BTG (LON:BTG) said today that it won CE Mark clearance in the European Union for its DC Bead Lumi radiopaque drug-eluting bead. The bead is designed to be loaded with doxorubicin or irinotecan to locally treat tumors in patients with hepatocellular carcinoma and malignant colorectal cancer metastasised to the liver.
The company’s DC Bead Lumi also features real-time visible confirmation of the bead’s location, which the company claims will enhance control in transarterial chemoembolisation procedures.
Get the full story at our sister site, Drug Delivery Business News.
The post BTG wins CE Mark for DC Bead Lumi radiopaque drug-eluting bead appeared first on MassDevice.